We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Issues PRIME Report Analyzing Its First Two Years
The item has been added to your shopping cart.
EMA Issues PRIME Report Analyzing Its First Two Years
The European Medicines Agency issued a report card on the first two years of its Priority Medicines (PRIME) Scheme, highlighting that it has received and processed 177 requests for eligibility for the program that provides early scientific and regulatory support for medicines based on promising preliminary clinical evidence.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor